News
Watch
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Daniel V. Catenacci, MD, University of Chicago

Articles by Daniel V. Catenacci, MD, University of Chicago

Is Frontline IO Therapy Appropriate in Gastric Cancer?

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Global Use of Frontline Therapy in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Trending on OncLive

FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma

European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer

Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer